Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials

Calvin Zhao, Akya Myrie, Zachary Feuer, Timothy Roberts, Scott E. Sherman, Marc A. Bjurlin, Richard S. Matulewicz

Research output: Contribution to journalArticlepeer-review

Abstract

Smoking is a causal or contributory factor for nearly all genitourinary cancers and exerts significant influence on treatment, quality of life, and survival outcomes. In order to understand the influence smoking has on the outcomes of contemporary therapies, pertinent smoking-related data must be systematically collected and report. We sought to determine how often and how rigorously smoking status is collected and reported in publications of clinical trials in genitourinary cancers by conducting a systematic review. Our initial search yielded 622 articles, 354 of which met criteria. The vast majority of included studies (91.8%) did not report any details about trial participants’ smoking status. When included, 96.3% of studies reported baseline status qualitatively. No studies used a validated measurement instrument or reported change in participants’ smoking status over the study period. Absence of the collection and reporting of smoking-related data precludes further study of how smoking impacts outcomes and highlights an important deficiency in GU oncology clinical trial design.

Original languageEnglish (US)
Article number102022
JournalCancer Epidemiology
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials'. Together they form a unique fingerprint.

Cite this